CD97-directed CAR-T cells

CD97-directed CAR-T cells are an investigational cell therapy in which patient or donor T cells are genetically modified to express a chimeric antigen receptor (CAR) targeting CD97, a protein broadly and highly expressed on acute myeloid leukemia (AML) cells relative to normal hematopoietic stem and progenitor cells. To prevent fratricide due to native CD97 expression on T cells, these CAR-T cells undergo knockout of the CD97 gene using CRISPR-Cas9 prior to CAR expression. Additional engineering—such as mutation of the CD3ζ domain—may further optimize persistence and anti-tumor activity. CD97-directed CAR-T cells elicit cytotoxic effects on AML in preclinical models, demonstrating activity against AML cell lines and primary patient AML cells while sparing most normal hematopoietic cells. This approach is being studied for AML due to the limited availability of selective antigens for CAR-T therapy in this disease[1].

Other names

CD97 CAR-T cellsCD-97 CAR-T cellsCD 97 CAR-T cellsCD97 KO CAR-T cellsCD-97 KO CAR-T cellsCD 97 KO CAR-T cells